← All cohorts · Ebola virus cohorts
PREVAIL III Ebola Survivor Cohort
source record (JSON) · schema v2.0.0 · CC BY 4.0
Design notes & limitations. Large observational natural-history cohort with a close-contact comparator, banked specimens, and up to 5 years of 6-monthly follow-up. Documented ocular (uveitis), musculoskeletal, neurologic and other sequelae plus viral persistence in immune-privileged sites. n_enrolled shown is the target survivor count; ~1,126 survivors enrolled by 2017 (plus ~2,700 contacts). Quantitative findings pending human extraction from source tables.
Identity & trigger
- Cohort id
prevail-iii-ebola- Aliases
- PREVAIL III, Partnership for Research on Ebola Virus in Liberia III
- Outbreak / event
- West Africa Ebola epidemic 2014–2016 (Liberia)
- Pathogen
- Ebola virus (Virus)
- Exposure ascertainment
- serology
Design
- Design
- Prospective (non-inception)
- Denominator defined
- Yes
- Denominator method
- Ebola virus disease survivors (antibody-confirmed) and their close contacts enrolled in Liberia and followed longitudinally.
- Recruitment
- Mixed
- Time zero
- Enrolment after recovery from acute Ebola virus disease (month)
- Control group
- Household contacts
Size & attrition
- Enrolled
- 1500
- Analysed / enrolled
- 1126/1500 (75%)
- Max follow-up (months)
- 60
Biospecimens
- Specimens
- Yes
- Types
- serum, plasma, other
- Acute-phase specimens
- No
- Biobank
- active
- External access
- collaboration only
Observations (1)
Functional outcomes
measured, not reported Proportion
- Measure
- Any persistent symptom func:any-persistent-symptom
- As worded
- “uveitis (ocular sequela) significantly more prevalent among survivors than close contacts”
- Population
- whole cohort · denominator Unclear · N=measured, not reported
- Timing
- 6 mo (3-6 mo) · ref Not reported
- Method
- Unclear
- Comparator
- no comparator
- Comparability signature
- 0132874c4c — measure func:any-persistent-symptom · Unclear · ref Not reported · denom Unclear · 3-6 mo · Proportion
- Provenance
- Results (uveitis among six symptoms significantly more common in survivors vs contacts; exact percentages pending extraction) · Manual · verified OSMF research-tracker (web-verified against source) on 2026-07-20
Extensions (Layer 3)
ebola validated
{"baseline_ocular_exam_n": 789, "uveitis_laterality": "not_reported"}
Publications
- PREVAIL III Study Group (2019). A Longitudinal Study of Ebola Sequelae in Liberia. New England Journal of Medicine. PMID 30855742 · DOI 10.1056/NEJMoa1805435 primary
Provenance & verification
- Registration
- NCT02431923
- Funders
- National Institute of Allergy and Infectious Diseases (NIAID/NIH), Liberian Ministry of Health
- Related cohorts
- none
- Symptom-inventory scope
- Targeted panel
- Last verified
- 2026-07-20 — OSMF research-tracker (web-verified against source)